INKEF Capital

Established in 2010, INKEF Capital is a prominent venture capital firm headquartered in Amsterdam, focusing on early-stage investments in technology and healthcare sectors. The firm is backed by Dutch pension fund ABP and manages approximately €500 million, making it one of the largest venture capital funds in the Netherlands. INKEF Capital is dedicated to supporting innovative companies with disruptive technologies and scalable business models, typically investing in Seed and Series A rounds, and occasionally in Series B.

INKEF Capital's investment strategy emphasizes long-term collaboration and active support for its portfolio companies. The firm provides strategic guidance and operational support, leveraging a broad network of industry experts and advisors to accelerate growth and enhance market leadership. This approach aims to navigate the complexities of scaling businesses in competitive global markets.

With a diverse portfolio of promising startups and growth-stage enterprises, INKEF Capital continues to drive innovation and foster the next generation of industry leaders. The firm's notable investments include Cashforce, a financial technology company, and Calypso Biotech, a biotechnology firm focused on immunological diseases. INKEF Capital's commitment to patient, long-term investment has been instrumental in the success of its portfolio companies, contributing to their growth and expansion across Europe and the United States.